Seneca Therapeutics, Inc.
PrivateLast Round
Series B
Extension
Aug 28, 2025
Est. Valuation
$51M
Total Funding Raised
$18.98M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Seneca Therapeutics, Inc. is a biotechnology company developing a pipeline of novel oncolytic immunotherapeutic cancer agents using the Seneca Valley Virus (SVV-001).
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Seneca Therapeutics, Inc. Comparables
Compare Seneca Therapeutics, Inc. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Virogin Biotech | 83% | |
| EpicentRx | 81% | |
| TILT Biotherapeutics | 79% |
For institutional investors. Book with your work email.
Seneca Therapeutics, Inc. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B Extension | Aug 28, 2025 | ||||
| Series B | Jun 27, 2025 | ||||
| Bridge | Mar 21, 2023 | ||||
| Convertible Debt | Jan 4, 2022 | ||||
| VC Round | Mar 1, 2021 | ||||
Series A | Jun 1, 2020 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Seneca Therapeutics, Inc. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| VisionTech Partners | Bridge, Series A |
| Accelerator Venture Partners | Series A |
| Keiretsu Capital | Bridge |
| Broad Street Angels | Series A |
| Keiretsu Forum Mid-Atlantic | Convertible Debt |
| MABA | Convertible Debt |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 20, 2026
Monthly visitors increased 31% MoM.
- Jul 25, 2026
Monthly visitors increased 49% MoM.
For institutional investors. Book with your work email.
Seneca Therapeutics, Inc. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Seneca Therapeutics, Inc.'s valuation, stock price, and market status.
Is Seneca Therapeutics, Inc. a public or private company?
Seneca Therapeutics, Inc. is a private company.
What is the current stock price of Seneca Therapeutics, Inc.?
Seneca Therapeutics, Inc. is a private company, so its shares have no public market price. Caplight tracks Seneca Therapeutics, Inc.'s secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Seneca Therapeutics, Inc. worth (valuation)?
Seneca Therapeutics, Inc.'s valuation is estimated at $51.0M based on funding round data.
Can I buy Seneca Therapeutics, Inc. stock?
Seneca Therapeutics, Inc. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Seneca Therapeutics, Inc.'s last funding round?
Seneca Therapeutics, Inc.'s most recent funding round was Series B Extension on August 28, 2025.
Who are the main investors in Seneca Therapeutics, Inc.?
Key investors in Seneca Therapeutics, Inc. include Keiretsu Capital.
Will Seneca Therapeutics, Inc. IPO soon?
No public IPO plans have been announced for Seneca Therapeutics, Inc..
How can I track Seneca Therapeutics, Inc. secondary market activity?
Caplight tracks bids, offers, and trades in Seneca Therapeutics, Inc.'s shares on secondary markets.